India Sovaldi Opposition Hearing Ends; EU Case Looms
This article was originally published in Scrip
Executive Summary
US-based not-for-profit group Initiative for Medicines, Access and Knowledge (I-MAK) believes that China's decision rejecting Gilead Sciences' patent application for sofosbuvir could buttress its Indian opposition case against the patent claim for the blockbuster hepatitis C therapy.